
Krystal Biotech Inc (NASDAQ:KRYS) shares have potential to nearly double from current levels, according to an analyst at BofA Securities.
The Krystal Biotech Analyst: Geoff Meacham initiated coverage of Krystal Biotech shares with a Buy rating and a $110 price target.